GE Healthcare Dharmacon has launched today more than one million new CRISPR-Cas9 gene editing products using an advanced new algorithm to design highly functional and specific reagents targeting most human, mouse and rat genes. The new products include predesigned synthetic CRISPR RNAs (crRNAs), single guide RNA (sgRNA) lentiviral particles and pooled sgRNA lentiviral particle libraries. These advances eliminate laborious and time consuming sequence selection, specificity checks, cloning and sequencing steps, allowing researchers to save time and focus on their experiments rather than reagent design.
The new technology uses data derived from thousands of gene editing laboratory experiments to identify characteristics of CRISPR reagents most likely to produce a functional change to the target gene. The Dharmacon development team also focused on specificity of gene editing, a critical attribute often overlooked or poorly addressed with previously available design tools. The design algorithm more accurately identifies and eliminates sequences with potential for ...
